Blood Preparation Market Size & Growth Forecast 2027–2036, By Segments (Product, Antithrombotic and Anticoagulants Type, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Blood Preparation Market size was valued at USD 56.8 billion in 2026 and is anticipated to grow at a 6.75% CAGR from 2027 to 2036, surpassing USD 109.15 billion by 2036. The industry revenue for 2027 is estimated at USD 60.03 billion.
Get more details on this report
Request Free Sample ReportBlood Preparation Market Intelligence Snapshot
Regional Market Dynamics
- North America leads due to mature transfusion infrastructure, extensive blood bank networks, and consistent demand for blood processing in surgical and emergency care settings.
- Asia Pacific growth at 7.35% CAGR is driven by expanding healthcare infrastructure, rising clinical utilization, and adoption of modern blood preparation and processing systems.
Segment Momentum
- Whole Blood accounted for 49.31% of the market in 2026 due to its broad clinical utility, established role in transfusion practices, and integration into standard collection, storage, and emergency care workflows.
- Fibrinolytics are the fastest-growing segment because they support rapid clot dissolution in acute care settings, where timely intervention is critical and treatment speed can significantly influence outcomes.
Market Expansion Drivers
- Rising prevalence of anemia and hematological disorders increasing transfusion and blood component demand.
- Expanding blood screening regulations accelerating adoption of validated preparation and testing technologies.
- Advancements in apheresis and plasma-derived therapy manufacturing strengthening blood component processing demand.
Leading Market Participants
- Top players in the blood preparation market include Pfizer Inc. (United States), Bristol-Myers Squibb Company (United States), Sanofi S.A. (France), AstraZeneca PLC (United Kingdom), Baxter International Inc. (United States), GlaxoSmithKline plc (United Kingdom), LEO Pharma A/S (Denmark), Portola Pharmaceuticals, Inc. (United States), Celgene Corporation (United States), Bayer AG (Germany).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 56.8 billion
- 2027 Estimated Market Size: USD 60.03 billion.
- Projected Market Size: USD 109.15 billion by 2036
- Growth Forecast: 6.75% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Whole Blood (Product) | Anticoagulants (Antithrombotic and Anticoagulants Type) | Thrombocytosis (Application)
- Emerging Opportunity Segment: Blood Derivatives (Product) | Fibrinolytics (Antithrombotic and Anticoagulants Type) | Angina Blood Vessel Complications (Application)
Market Growth Drivers and Industry Trends
Rising prevalence of anemia and hematological disorders increasing transfusion and blood component demand
The rising burden of anemia and hematological disorders will drive the blood preparation market growth by increasing the need for reliable transfusion support and availability of separated blood components. Patients with chronic anemia, blood loss, and other hematological conditions frequently require red blood cells, platelets, plasma, or other blood products tailored to their clinical needs. This growing demand places greater emphasis on efficient collection, separation, processing, and storage procedures that can maintain component quality while supporting timely clinical use. Hospitals and blood centers therefore require dependable preparation systems capable of handling increasing transfusion volumes and producing standardized components for different therapeutic applications.
Expanding blood screening regulations accelerating adoption of validated preparation and testing technologies
Stronger requirements for blood safety and infectious disease screening are encouraging healthcare facilities to adopt validated processing and testing workflows, supporting growth of the blood preparation market. Regulatory emphasis on donor screening, pathogen detection, component quality, and traceability requires blood centers to maintain consistent procedures throughout collection and preparation. Advanced technologies help automate critical preparation and testing steps, reduce the risk of processing errors, and support compliance with established safety protocols. As screening requirements become more comprehensive, facilities are also placing greater value on integrated systems that can improve quality control while maintaining efficient blood component processing.
Advancements in apheresis and plasma-derived therapy manufacturing strengthening blood component processing demand
Technological progress in apheresis is expanding the ability to collect specific blood components directly from donors, while improvements in plasma-derived therapy manufacturing are increasing the importance of high-quality plasma processing. These developments will propel the blood preparation market growth as healthcare providers seek more targeted collection methods and manufacturers require consistent plasma inputs for therapeutic applications. Modern apheresis systems can selectively collect platelets, plasma, or other components while returning remaining blood constituents to the donor, improving the efficiency of component collection. At the same time, more sophisticated downstream processing requirements are encouraging investment in equipment and workflows that preserve plasma quality and support controlled component manufacturing.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of anemia and hematological disorders increasing transfusion and blood component demand | 2.00% | High | North America, Asia Pacific | High | Near Term |
| Expanding blood screening regulations accelerating adoption of validated preparation and testing technologies | 1.70% | High | Europe, Asia Pacific | Medium | Mid Term |
| Advancements in apheresis and plasma-derived therapy manufacturing strengthening blood component processing demand | 1.30% | Moderate | North America, Europe | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held the largest share of the blood preparation market in 2026, supported by well-established blood collection and processing infrastructure, advanced healthcare systems, and strong demand for safe and efficient blood component management. The region benefits from widespread adoption of automated preparation technologies, stringent quality and safety requirements, and continued investments in modernizing transfusion services. High awareness of blood safety protocols and the increasing need for reliable blood component availability across hospitals and diagnostic facilities further reinforce the region’s market position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is expected to represent the fastest-growing regional market, driven by expanding healthcare infrastructure, improving access to transfusion services, and rising demand for blood components across developing healthcare systems. Increasing investments in hospital capacity, greater emphasis on blood safety, and the modernization of collection and processing facilities are supporting technology adoption. Growing healthcare expenditure and efforts to strengthen emergency and surgical care are also creating favorable conditions for wider use of advanced blood preparation solutions.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Quality Blood ComponentsGermany prioritizes standardized blood preparation procedures supported by advanced processing equipment and rigorous quality controls. German healthcare organizations continue optimizing blood collection and component manufacturing to strengthen transfusion services.
France 🇫🇷
Efficient Blood ManagementFrance continues strengthening blood preparation through modern processing technologies and coordinated blood service networks. French healthcare providers focus on maintaining high-quality blood components while supporting efficient distribution across medical facilities.
Italy 🇮🇹
Transfusion Infrastructure SupportItaly is improving blood preparation capabilities through equipment modernization and enhanced laboratory workflows. Italian blood service organizations continue reinforcing quality standards to support dependable transfusion practices across healthcare facilities.
Japan 🇯🇵
Safe Transfusion PracticesJapan focuses on highly controlled blood preparation processes that support reliable transfusion outcomes. Japanese blood service organizations continue investing in automated technologies and quality monitoring to improve processing consistency and product safety.
South Korea 🇰🇷
Automated Collection SystemsSouth Korea is expanding automated blood processing and component preparation capabilities across healthcare institutions. South Korean blood centers emphasize operational efficiency, quality assurance, and reliable supply management for transfusion services.
United States 🇺🇸
Advanced Blood ProcessingThe U.S. blood preparation market emphasizes automated processing technologies, component separation, and strong quality management practices. Blood centers across the U.S. continue improving operational efficiency while supporting growing clinical demand for specialized blood components.
Segment Leadership and Growth Trends
Blood Preparation Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Whole Blood (Largest Segment) vs Blood Derivatives (Fastest-Growing Segment)
Whole blood represented the largest share of 49.31% in 2026 in the blood preparation market, reflecting its essential role in transfusion medicine and the treatment of patients requiring replacement of blood components. Demand is supported by surgical procedures, trauma care, emergency medicine, and other clinical situations in which rapid restoration of blood volume and oxygen-carrying capacity is required. Established blood collection and transfusion infrastructure, together with continued emphasis on maintaining adequate blood supplies, reinforces the position of whole blood within the broader blood preparation landscape.
Blood derivatives are gaining momentum as healthcare systems increasingly favor targeted therapeutic use of separated blood components and plasma-derived products. Processing blood into specialized derivatives enables healthcare providers to address specific clinical requirements while improving the functional utilization of collected blood resources. Growing demand for therapies based on plasma proteins and other blood-derived components, alongside advances in processing and fractionation technologies, is supporting greater adoption of blood derivatives across healthcare applications.
Antithrombotic and Anticoagulants Type Segment Analysis: Anticoagulants (Largest Segment) vs Fibrinolytics (Fastest-Growing Segment)
The anticoagulants segment dominated the blood preparation market with a 62.37% share in 2026, reflecting the widespread clinical need to prevent and manage abnormal blood clot formation. Anticoagulants are extensively used in the management of thromboembolic conditions and in situations where reducing clot-related complications is a key therapeutic objective. Rising awareness of cardiovascular and thrombotic disorders, combined with broader use of anticoagulant therapy across acute and long-term care, continues to support demand for this segment.
Fibrinolytics are experiencing faster growth as healthcare providers increasingly require therapies capable of rapidly addressing established blood clots in critical clinical situations. Their role in restoring blood flow during acute thrombotic events makes them particularly relevant in time-sensitive cardiovascular and cerebrovascular care. Improvements in emergency treatment protocols, greater awareness of rapid intervention, and continued advances in thrombolytic therapies are contributing to broader utilization of fibrinolytics and strengthening their growth prospects within the market.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Whole Blood, Blood Components, Blood Derivatives | Whole Blood | Blood Derivatives |
| Antithrombotic and Anticoagulants Type | Platelet Aggregation Inhibitors, Fibrinolytics, Anticoagulants | Anticoagulants | Fibrinolytics |
| Application | Thrombocytosis, Pulmonary Embolism, Renal Impairment, Angina Blood Vessel Complications, Others | Thrombocytosis | Angina Blood Vessel Complications |
Competitive Landscape and Market Positioning
Major players in the blood preparation market:
1. Pfizer Inc. (United States)
2. Bristol-Myers Squibb Company (United States)
3. Sanofi S.A. (France)
4. AstraZeneca PLC (United Kingdom)
5. Baxter International Inc. (United States)
6. GlaxoSmithKline plc (United Kingdom)
7. LEO Pharma A/S (Denmark)
8. Portola Pharmaceuticals Inc. (United States)
9. Celgene Corporation (United States)
10. Bayer AG (Germany)
The blood preparation market is witnessing continuous advancements supported by collaborative development efforts and increasing investment in improved blood processing technologies. Industry participants are focusing on enhancing safety, storage stability, and separation efficiency to address evolving transfusion and clinical care requirements. Expansion into emerging healthcare facilities and laboratory networks is also contributing to broader adoption of advanced preparation systems.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. (United States) | |||||||
| Bristol-Myers Squibb Company (United States) | |||||||
| Sanofi S.A. (France) | |||||||
| AstraZeneca PLC (United Kingdom) | |||||||
| Baxter International Inc. (United States) | |||||||
| GlaxoSmithKline plc (United Kingdom) | |||||||
| LEO Pharma A/S (Denmark) | |||||||
| Portola Pharmaceuticals Inc. (United States) | |||||||
| Celgene Corporation (United States) | |||||||
| Bayer AG (Germany). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| bioMérieux | Jun-25 | bioMérieux acquired the assets and technologies of Day Zero Diagnostics, integrating advanced sequencing and bioinformatics tools into its R&D pipeline. The transaction adds critical direct-from-whole-blood sample preparation workflows capable of identifying bacterial pathogens and antibiotic resistance profiles within hours, representing a significant technological shift toward rapid, precision-based infectious disease diagnostics. |
| DHL Group | Mar-25 | DHL Group acquired CRYOPDP, a specialized provider of temperature-controlled logistics for the life sciences sector. This acquisition significantly expands the company's global cold-chain capacity for the transport of time-sensitive blood products and cell therapies across 15 countries, addressing critical infrastructure needs for emerging advanced medical therapies. |
| Terumo Blood and Cell Technologies | Feb-25 | Terumo Blood and Cell Technologies launched the Reveos system in the United States in partnership with Blood Centers of America. The system automates the separation of whole blood into four distinct components in a single spin, significantly increasing throughput and consistency in blood processing while reducing labor requirements for large-scale blood centers. |
| Haemonetics Corporation | Jan-25 | Haemonetics Corporation completed the divestiture of its whole-blood collection assets to GVS for USD 67.8 million. The transaction is a strategic move to optimize the company’s portfolio, allowing it to reallocate resources and focus exclusively on high-growth segments such as apheresis and plasma collection technologies. |
| Accelerate Diagnostics | Oct-24 | Accelerate Diagnostics received FDA 510(k) clearance for its Accelerate Arc System, a platform designed to streamline positive blood culture sample preparation. By eliminating the need for traditional overnight subculturing and integrating directly with MALDI-based microbial identification systems, the platform accelerates the diagnostic turnaround time for sepsis management and critical blood-borne infections. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Blood Preparation Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Collection Method | Whole Blood Collection, Apheresis Collection, Autologous Collection |
| Donor Type | Voluntary Unpaid Donors, Replacement Donors, Paid Donors, Autologous Donors |
| Healthcare Setting | Hospitals, Blood Banks, Diagnostic & Reference Laboratories, Specialty Clinics |
Blood Preparation Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Blood Center Modernization Strategy |
|
| Blood Processing Automation Adoption |
|
| Voluntary Blood Donation Ecosystem |
|
Need a different cut of the data?
Request Custom ResearchHow much is the blood preparation market worth?
How is the blood preparation industry projected to perform over the next decade?
How are stricter blood screening regulations reshaping investment priorities in the blood preparation market?
Why are specialized blood component processing technologies gaining importance in the blood preparation market?
Why does Whole Blood hold the largest share of the blood preparation market?
What is driving the growth of Fibrinolytics in the blood preparation market?
Why does North America lead the blood preparation market?
What is driving growth in Asia Pacific for the blood preparation market?
What are the key competitors in the blood preparation landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization